1. Home
  2. ELVA vs CTNM Comparison

ELVA vs CTNM Comparison

Compare ELVA & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Electrovaya Inc.

ELVA

Electrovaya Inc.

N/A

Current Price

$8.49

Market Cap

359.5M

Sector

N/A

ML Signal

N/A

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

N/A

Current Price

$14.78

Market Cap

507.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ELVA
CTNM
Founded
1996
2009
Country
Canada
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
359.5M
507.0M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
ELVA
CTNM
Price
$8.49
$14.78
Analyst Decision
Buy
Buy
Analyst Count
1
5
Target Price
$14.00
$19.80
AVG Volume (30 Days)
435.4K
169.1K
Earning Date
01-01-0001
06-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$33.92
N/A
Revenue Next Year
$56.86
N/A
P/E Ratio
$78.51
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.30
$3.35
52 Week High
$11.88
$16.33

Technical Indicators

Market Signals
Indicator
ELVA
CTNM
Relative Strength Index (RSI) 52.54 53.33
Support Level $8.11 $13.86
Resistance Level $9.12 $16.17
Average True Range (ATR) 0.51 0.97
MACD 0.09 -0.26
Stochastic Oscillator 94.74 51.76

Price Performance

Historical Comparison
ELVA
CTNM

About ELVA Electrovaya Inc.

Electrovaya Inc is a technology-focused lithium-ion battery company engaged in designing, developing and manufacturing battery cells, modules and systems based on its proprietary Infinity Battery Technology, which provides high safety performance, long cycle life and durability. The Company supplies low-voltage and high-voltage battery systems for industrial and transportation markets, including material-handling equipment, robotic vehicles, electric buses and trucks, and energy-storage installations, and its products are suitable for mission-critical applications. it maintains an expanding intellectual-property portfolio, develops next-generation solid-state and hybrid solid-state battery technologies, and sells its products through OEM relationships, dealer networks and direct sales.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: